Summary

Elypta has secured significant funding of 13.6 million euros in a groundbreaking pan-European initiative for early cancer detection, targeting individuals with Lynch Syndrome. The project, PREDI-LYNCH, aims to transform the early detection of cancers linked to this condition through a landmark European initiative. By receiving this substantial EU investment, Elypta is preparing to reach an annual study end date that represents the largest kidney cancer recurrence monitoring study in its history. This strategic financial commitment enables the team to transition from preliminary research into a commercial model with a focus on the urinary tract. The company is actively seeking academic partners and industry collaboration to develop companion diagnostics that offer clinical applications to the wider medical community.

Title

Elypta – Advancing Cancer Detection

Description

Our mission is to prevent cancer mortality through early detection by pioneering a metabolism-based liquid biopsy.

Keywords

cancer, team, detection, more, studies, study, science, news, careers, contact, metabolism, european, kidney, board, directors, urine, test

NS Lookup

A 198.202.211.1

Dates

Created 2026-04-14

Updated 2026-04-14

Summarized None